Chief Scientific Officer · Nurix Therapeutics, Inc. · Common Stock
Side
M
Value
—
Shares
2,858
Price
—
Executed
Apr 30, 2026
Disclosed
Apr 30, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Apr 30 executedApr 30, 2026 disclosed
NRIX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 2.4% of prior position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Hansen Gwenn filed this Form 4 reporting a option exercise of NRIX on Apr 30, 2026. It became public on Apr 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Scientific Officer
Hansen Gwenncik:0001817160
Issuer
Nurix Therapeutics, Inc.cik:0001549595
Revision history · 0
No field has changed since this record was first ingested.
